Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expression

Biochemical and Biophysical Research Communications

Volumn 414, Issue 1, 2011, Pages 129-134

  Zhang, Yi ^a,b   Cheng, Yan ^a   Zhang, Li ^b   Ren, Xingcong ^a   Huber Keener, Kathryn J ^a   Lee, Sang ^a   Yun, Jong ^a   Wang, Hong Gang ^a   Yang, Jin Ming ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl xl; EEF 2 kinase; Glioblastoma; TRAIL

Indexed keywords

1 HEXADECYL 2 METHYL 3 (PHENYLMETHYL) 1H IMIDAZOLIUM IODIDE; ELONGATION FACTOR 2 KINASE; NH 125; PROTEIN BCL XL; PROTEIN SERINE THREONINE KINASE INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

BCL-X PROTEIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ELONGATION FACTOR 2 KINASE; GENE TARGETING; GLIOMA; HUMANS; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 80054061981     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.038     Document Type: Article

References (23)

1. Prados M.D., Levin V. Biology and treatment of malignant glioma. Semin. Oncol. 2000, 27:1-10.
2. Bellail A.C., Qi L., Mulligan P., Chhabra V., Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials 2009, 4:34-41.
3. Bellail A.C., Tse M.C., Song J.H., Phuphanich S., Olson J.J., Sun S.Y., Hao C. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J. Cell Mol. Med. 2010, 14:1303-1317.
4. Hao C., Beguinot F., Condorelli G., Trencia A., Van Meir E.G., Yong V.W., Parney I.F., Roa W.H., Petruk K.C. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res. 2001, 61:1162-1170.
5. Ryazanov A.G., Rudkin B.B., Spirin A.S. Regulation of protein synthesis at the elongation stage. New insights into the control of gene expression in eukaryotes. FEBS Lett. 1991, 285:170-175.
6. Parmer T.G., Ward M.D., Yurkow E.J., Vyas V.H., Kearney T.J., Hait W.N. Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer. Br. J. Cancer 1999, 79:59-64.
7. Wu H., Yang J.M., Jin S., Zhang H., Hait W.N. Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Cancer Res. 2006, 66:3015-3023.
8. Zhang L., Zhang Y., Liu X.Y., Qin Z.H., Yang J.M. Expression of elongation factor-2 kinase contributes to anoikis resistance and invasion of human glioma cells. Acta Pharmacol. Sin. 2011, 32:361-367.
9. Cheng Y., Li H., Ren X., Niu T., Hait W.N., Yang J. Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition. PLoS One 2010, 5:e9715.
10. Cheng Y., Ren X., Zhang Y., Patel R., Sharma A., Wu H., Robertson G.P., Yan L., Rubin E., Yang J.M. eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206. Cancer Res. 2011, 71:2654-2663.
11. Wu H., Zhu H., Liu D.X., Niu T.K., Ren X., Patel R., Hait W.N., Yang J.M. Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-d-glucose against human glioma cells through blunting of autophagy. Cancer Res. 2009, 69:2453-2460.
12. Fulda S., Meyer E., Debatin K.M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002, 21:2283-2294.
13. Buchsbaum D.J., Zhou T., Lobuglio A.F. TRAIL receptor-targeted therapy. Future Oncol. 2006, 2:493-508.
14. Dong Y., Yin S., Li J., Jiang C., Ye M., Hu H. Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway. Apoptosis 2011, 16:394-403.
15. Karasic T.B., Hei T.K., Ivanov V.N. Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma. Exp. Cell Res. 2010, 316:1994-2007.
16. Zhang L., Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005, 12:228-237.
17. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., Peng T.I., Jones D.P., Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997, 275:1129-1132.
18. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2:647-656.
19. Liu F., Hu X., Zimmerman M., Waller J.L., Wu P., Hayes-Jordan A., Lev D., Liu K. TNFalpha cooperates with IFN-gamma to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis. PLoS One 2011, 6:e16241.
20. Walensky L.D. BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ. 2006, 13:1339-1350.
21. Griffiths G.J., Koh M.Y., Brunton V.G., Cawthorne C., Reeves N.A., Greaves M., Tilby M.J., Pearson D.G., Ottley C.J., Workman P., Frame M.C., Dive C. Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J. Biol. Chem. 2004, 279:46113-46121.
22. Ray S., Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res. 2003, 63:4713-4723.
23. Yin D., Zhou H., Kumagai T., Liu G., Ong J.M., Black K.L., Koeffler H.P. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005, 24:344-354.